Scientific Program

Registration: 07:00 - 08:00First Session 08:00 - 08:30 Breast Cancer - HER2/ER+ Moderators: Tayeb Sabir Kareem - Nariman Muhammad Fatah - Hawar Hassan

Time Abstract08:00 - 08:10 164642:

A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancerKakil Rasul (Kurdistan-Iraq)

08:10 - 08:20 165131:PALOMA-2: Primary results from a phase 3 trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).Hazha Abdullah M. Ameen (Kurdistan-Iraq)

08:20 - 08:30 166834:Pathologic complete response rates after neoadjuvant trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + trastuzumab + pertuzumab treatment in patients with HER2-positive early breast cancer (KRISTINE). Sarkawt Khosnaw (Kurdistan-Iraq)

October

20Thursday

DAY 1

Second Session 08:30 - 09:10 Breast Cancer - Triple-Negative/Cytotoxic Chemotherapy/Local Therapy

Moderators: Tayeb Sabir Kareem - Nariman Muhammad Fatah - Hawar HassanTime Abstract

08:30 - 08:40 166500:Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline / taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.Ramadhan T. Othman (Kurdistan-Iraq)

08:40 - 08:50 170337:Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance).Sardar Hassan Arif (Kurdistan-Iraq)

08:50 - 09:00 170268:A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01).Tahir Hawramy (Kurdistan-Iraq)

09:00 - 09:10 Panel Discussion

Third Session 09:10 - 09:40 Gastrointestinal (Colorectal) CancerModerators: Saeb Gaylany - Hazim Sadiq - Razhan Foad

Time Abstract09:10 - 09:20 161936:

Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). Jamal Khader (Jordan)

09:20 - 09:30 168547:FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized study—Prodige 14 – Accord 21 (METHEP-2), a UNICANCER GI trial. Jamal Khader (Jordan)

09:30 - 09:40 Panel Discussion

Fourth Session 09:40 - 10:30 Genitourinary (Nonprostate) CancerModerators: Basak Barzngy - Nwraddin Ismail - Hussein Qadir

Time Abstract09:40 - 09:50 171166:

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB 80802 (Alliance).Alper Ata (Turkey)

09:50 - 10:00 161936:Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).Alper Ata (Turkey)

10:00 - 10:10 165706:A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study.May Mabro (France)

10:10 - 10:20 162546:ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. May Mabro (France)

10:20 - 10:30 Panel Discussion11:00 - 12:00 Opening Ceremony 12:00 -12:30 Conference Reception and Exhibition Opening

Fifth Session 12:30 - 13:10 Lung Cancer – Non-Small CellModerators: Aram Baram - Bashar Hanna - Sami Ahmed

Time Abstract12:30 - 12:40 167889:

Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). Kakil Rasul (Kurdistan - Iraq)

12:40 - 12:50 167434:Primary analysis for alectinib versus crizotinib in ALK-inhibitor naïve ALK positive non-small cell lung cancer (ALK+ NSCLC) in randomized open-label phase III trial (J-ALEX study). Luqman R. Sulaiman (Kurdistan-iraq)

12:50 - 13:00 165387:CONVERT: An international randomised controlled trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy (RT) schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS) (NCT00433563).Layth Y. I. Mula-Hussain (Kurdistan - Iraq)

13:00 - 13:10 Panel Discussion13:10 - 14:20 Lunch Break

Sixth Session 14:20 - 15:10 Head and Neck CancerModerators: Firas Abdulla M. Ali - Karim Faruq - Abdulmuneem Ahmad

Time Abstract14:20 - 14:30 164086:

Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial.Rezvan Abduljabbar (Kurdistan - Iraq)

14:30 - 14:40 170084:Induction taxotere platinum 5-FU (TPF) followed by cetuximab-radiotherapy versus concurrent chemoradiotherapy in patients with N2b-N3 (non operated Stage III-IV) squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial. Ömer Erol Uzel (Turkey)

14:40 - 14:50 164984:Nivolumab versus therapy of investigator’s choice (IC) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.Mohammad Saleem Mohammed (Kurdistan - Iraq)

14:50 - 15:00 166094:Preliminary results from KEYNOTE-055: pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).Shwan Salam Marouf (Kurdistan - Iraq)

15:00 - 15:10 Panel DiscussionEnd of First Scientific Day

Seventh Session 15:10 - 16:05 Surgical SessionModerators: Abas Rashed - Firas Abdulla - Bashar Hanna Azar

Time Abstract15:10 - 15:20 A Focus on Lung Cancer surgery – Recent Updates and the Current Standards

of Care. Prof. Dr. Cemal Asım Kutlu (Turkey)

15:20 - 15:30 Surgica treatments for bone sarcoma (STS): Time for a new strategy?Kaveh Gharanizadeh (Iran)

15:30 - 15:40 Management of Margin/Margins Involvement after Breast Conserving Surgery (Personal Experience) Jamal Marouf (Kurdistan - Iraq)

15:40 - 15:50 Role of surgery in newly diagnosed and Recurrent glioblastoma: Recent strides Prof. Gokhan AKDEMIR (Turkey)

15:50 - 16:05 Panel DiscussionEnd of Scientific Program Day 1

16:15 - 18:00 Companies SymposiumsModerators: Firas Abdulla M. Ali - Karim Faruq - Abdulmuneem Ahmad

Time Abstract16:15 - 16:40 Sanofi Symposium: 166318 - (Cabazitaxel vs docetaxel in chemotherapy-naïve

(CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A 3-arm phase III study (FIRSTANA).Genitourinary (Prostate) Cancer.

16:40 - 16:45 Panel Discussion16:45 - 17:00 Coffee Break17:00 - 17:20 Janssen Symposium: Abiraterone acetate plus low dose prednisone improves

overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after chemotherapy

17:20 - 17:25 Panel Discussion

17:25 - 17:50 MSD Symposium: Immunotherapy in Lung Cancer

17:50 - 18:00 Panel Discussion

Followed by Dinner in Al Bustan Restaurant - Rotana Hotel at 20:30

Registration: 07:00 - 08:00First Session 08:00 - 08:40 Melanoma/Skin CancersModerators: Dindar Sharif Qurtas - Rozhan Omer - Siham Tahir Amedy

Time Abstract08:00 - 08:10 167363:

3-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE001.TAMER EL NAHHAZ (Egypt)

08:10 - 08:20 167092:Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.TAMER EL NAHHAZ (Egypt)

08:20 - 08:30 165198:Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE006. Nabil Chamssedine (Lebanon)

08:30 - 08:40 Panel Discussion

Second Session 08:40 - 09:20 Patient and Survivor CareModerators: Muhamad Salem - Luay Saoour - Luqman Rahman Shal

Time Abstract08:40 - 08:50 162825:

Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials. Nabil Chamssedine (Lebanon)

08:50 - 09:00 170470:A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients. Rozhan Omar (Kurdistan - iraq)

09:00 - 09:10 161961:Placebo-controlled phase III study comparing dexamethasone on day1 to on day1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy. Alaa Othaman Sedeeq (Kurdistan - iraq)

09:10- 09:20 Panel Discussion09:20 - 09:35 Coffee Break & Visiting the Exhibition

October

21Friday

DAY 2

Third Session 09:35 - 10:15 Genitourinary (Prostate) CancerModerators: Ismael Hama Ameen - Nafea Taha Salih - Pshtiwan Hashm Bazaz

Time Abstract09:35 - 09:45 166318

Cabazitaxel vs docetaxel in chemotherapy-naïve (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A 3-arm phase III study (FIRSTANA). Christine Théodore (France)

09:45 - 09:55 166934A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12. Christine Théodore (France)

09:55 - 10:05 165234A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. Abdul Muniem Ahmed Mahdi (Kurdistan - Iraq)

10:05 - 10: 15 Panel Discussion

Fourth Session 10:15 - 10:40 Genitourinary (Nonprostate) CancerModerators: Ismael Hama Ameen - Nafea Taha Salih - Pshtiwan Hashm Bazaz

Time Abstract10:15 - 10:25 167275

Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC). Fadi Sami Farhat (Lebanon)

10:25 - 10:35 170759Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.</span. Fadi Sami Farhat (Lebanon)

10:35 - 10:40 Panel Discussion

Fifth Session 10:40 - 11:10 Gynecologic CancerModerators: Ariana Khalis Jawad - Alla Yousif Mahmood - Khalida M. Amin

Time Abstract10:40 - 10:50 166142

Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. Saad Tahir (UK)

10:50 - 11:00 168863OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). Saad Tahir (UK)

11:00 - 11:10 Panel Discussion

Sixth Session 11:10 - 12:00 Hematologic Malignancies- Lymphoma and Chronic Lymphocytic Lymphoma

Moderators: Ismael Hama Ameen - Nafea Taha Salih - Pshtiwan Hashm BazazTime Abstract

11:10 - 11:20 164161Randomized phase III study on the effect of early intensification of rituximab in combination with 2weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large Bcell lymphoma: Results from a HOVON-Nordic Lymphoma Group study. Anwar Qadir Sheikha (Kurdistan - Iraq)

11:20 - 11:30 169547Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase 2 study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). Ahmed Khudair Yassin (Kurdistan - Iraq)

11:30 - 11:40 165119A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma.Zaki Barwari (Kurdistan - Iraq)

11:40 - 11:50 163467PILLAR-2: A randomized, double-blind, placebo-controlled, phase 3 study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).Mohamed Daher Ali (Kurdistan - Iraq)

11:50 - 12:00 Panel Discussion12:00 - 14:00 AstraZeneca Lunch Symposium : Latest Evidence and Updates on Role of

Faslodex in Management of Post-menopausal Breast CancerNabil Chamseddine - Lebanon

Seventh Session 14:00 - 14 :40

Educational SessionLung

Moderators: Sarkawt Khoshnaw - Aram Baram - Layth Y. I. Mula-HussainTime Abstract

14:00 - 14:10 Biology of Small Cell Lung CancerKakil Rasul (Kurdistan - Iraq)

14:10 - 14:20 Small Cell Lung Cancer and RadiotherapyÖmer Erol Uzel (Turkey)

14:20 - 14:30 Current and Future Approaches to the Systemic Therapy of Small Cell Lung CancerKakil Rasul (Kurdistan - Iraq)

14:30 - 14:40 Panel Discussion

Eighth Session 14:40 - 15:30 Educational SessionColorectal

Moderators: Basak Barzngy - Daryia Ahmad - Hazim SadiqTime Abstract

14:40 - 14:50 RAS Wild-Type Patients Should Receive Anti-VEGF Therapy in First LineHazha Abdullah M. Ameen (Kurdistan-Iraq)

14:50 - 15:00 Treatment of RAS Wild-Type Patients with Anti-EGFR First Line TherapyMay Mabro (France)

15:00 - 15:10 Treatment Holidays Are the Standard of careDr. Fadi Sami Farhat (Lebanon)

15:10 - 15:20 Debating Current Controversies in the Management of Metastatic Colorectal Cancer: Maintenance Therapy Is the Standard!Jangi Shawkat Salai (Kurdistan - Iraq)

15:20 - 15:30 Panel DiscussionClosing Remarks